% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

  • merlin1990 Jan 5, 2013 12:38 AM Flag

    What's the compound name for z106?

    I am almost convinced to buy this stock, but I don't want surprises at the end. So, I would like to do my own diligence and research more about the potential of this clinical drug. I was kind of surprise that the website did not list the other name for z106. For example, Savient's krystexxa list pegloticase as the compound name, what about z106??

    I don't want to invest in a compound/drug that has been around for decades passed from one biopharma to another. Even if it will be approved, it won't be safe, and most likely there is a problem with the drug. I'd hate to support something that will cause harm to our society.

    Anyone please help me?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • One more thing. TP Snutch was recognized by Pfizer back in 6/2012 for his neuropathic pain research. He is very bright and big pharma is watching the drugs he developed for Zalicus.

      "Fifth Annual Awards Competition Dedicated to Independent Pain Research

      KIRKLAND, QC, June 12, 2012 /CNW/ - Pfizer Canada is pleased to announce the recipients of the 2011 Neuropathic Pain Research Awards, an annual grant competition for independent research in the areas of basic biomedical, clinical and health service and systems sciences.

      "For the past five years, the Neuropathic Pain Research Awards have supported Canadian medical innovation and research in neuropathic pain," says Lorella Garofalo, Director, Medical Affairs, Pfizer Canada.

      The awards provide funding grants to outstanding research that has the potential to improve the quality of life of people living with neuropathic pain (NeP), a common pain condition estimated to affect over one million Canadians.It is both incredibly painful and difficult to diagnose as there are a number of conditions that must first be ruled out.

      "Patients with neuropathic pain will have symptoms like burning, tingling or shocks,but beyond physical pain, this condition affects a person's emotional, social and financial well being," says Garofalo. "By some estimates, Canadians with NeP lose $2,567 every three months as a result of lost productivity and other consequences of their pain."

    • First you need to get the name right. It is Z-160, aka NMED-160.

      TP Snutch is what is behind the science of their ion channel research:

      Search and find Snutchlab and you will find the scientist behind their Ion Channel research.

      Here is some spoon feeding from their website.

      "Dr. Snutch, a Senior Scientific Advisor to Zalicus and the founder of Neuromed, is a professor in the Michael Smith Laboratories at the University of British Columbia. He was the first scientist in the world to describe the molecular basis for clinically important calcium channels in the cardiovascular, endocrine and nervous systems.

      Dr. Snutch's contributions have been recognized internationally with numerous awards, including the International Albrecht Fleckenstein Award, the Killam Research Prize, the Steacie Prize, and induction into the Royal Society of Canada. He was named 2004 Researcher of the Year by BC Biotech and has received the BC Innovation Council's New Frontiers in Research Award. Most recently, Dr. Snutch received an Honorary Doctorate of Science from Simon Fraser University."

      Also, go look at our famous stock lasar guy who flip flops his opinion to day trade. He has provided a lot of info about this compound.

      December 7, 2011, from SA

      In the absence of fanfare, the company accurately portrayed themselves as "a leader" (Ibid) in ion channel research. The subtlety of "a" versus "the," though less flattering, was more accurate given that their competition (e.g. Icagen-Pfizer (PFE), Convergence spun off by Glaxo-Smith-Kline (GSK), and little Hydra BioSciences) is slightly ahead of them in clinical trials. But that said, Zalicus is once again on the move and should gain ground on its competitors.

      The modest pop in the price per share seems to be the clarion call of a biotech company that refuses to give up. Z160, once NMED-160, has had a long and arduous history, but a history I have the utmost respect for.

      Company CSO Dr. Terrance Snutch, and the scientific core of an equally impressive list of ion channel leaders in research and academia (e.g. GW Zaponi, H Pajouhesh, ME Hildebrand, SM Cain et al.), was renowned in Canada for the introduction of NMED-160, when Merck partnered with then Neuromed for a lion's share in the development of the N-type ion channel drug candidate invented and targeted to block pain. But alas, NMED-160 ran into solubility and bioavailability problems, and Merck made a wider research decision to walk away from ion channel research.

      Neuromed was stung, and Dr. Snutch, a brilliant thinker and bullish inventor, refused to go away defeated. With the help of European scientists and the cash infusion from Exalgo's $40M milestone, here in 2011, NMED-160 has been modified into what is now known as Z160. Ultimately, it could win Dr. Snutch the Nobel prize for what it could mean to pain sufferers addicted to opioids.
      Therefore, in all fairness to Zalicus, this announcement deserves far more fanfare than it is being given. NMED-160 went in Phase 2 and was tested in 200 plus patients before being withdrawn, so when the company states they expect to quickly move through Phase I, investors should believe them. Zalicus is fine-tuning Z160 in this Phase 1 study; when it moves to Phase 2, I already expect positive results. Of course, only science and data can prove that, but I am among those believers who see Z160 making it to Phase 3.

      But as another poster has often reminded me, the odds of success for any biotech candidate is slim; I concur, yet I also know that Z160 has a head-start. With good safety data in hand from Phase 1, I venture the scientists in Zalicus-Vancouver, British Columbia, already have a good handle on its pain-mitigating efficacy.

      In conclusion, I also look forward to what the company may advance forward in its sodium and T-type channel research. Zalicus has mentioned other Z- ion channel types, but has kept that information closely guarded.

      • 1 Reply to steelingmoney
      • Now one more thing. NMED-160 was withdrawn because of bioavailability issues and Merck cancelled a 500MM agreement with NMED. Now that those bioavailability issues have been corrected as mentioned by the european scientists, with bioavailability going up 10 fold, we now have a drug that is potentially worth much more because it was only in phase 1 back then and is now in phase II. Consider the billions that big pharma is throwing around today to expand their pipeline, and it could be worth much more in today's terms.